CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 40 enrolled
Drug / intervention
Octreotide +1 moredrug
Likely dose
Octreotide 100mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02381249
NCT02381249N/ACompleted

The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery

St. James's Hospital, Ireland·interventional·Posted Mar 6, 2015·Updated Nov 27, 2023

In Brief

A clinical study evaluating Octreotide and Placebo for Esophageal Neoplasms and 5 related conditions. Completed, enrolled 40 participants across 2 sites in 2 countries.

Detailed Summary

Improvements to treatment strategies for patients with cancers of the upper gastrointestinal tract have produced a large population of people who remain free from cancer recurrence in the long term following treatment. Surgery is the cornerstone of treatment for patients with these cancers, but while surgical removal of the tumour may offer the best chance of cure, these are major operations associated with specific long term complications. Weight loss and poor nutrition are common problems among patients who attain long-term cancer remission and cure after surgery. The mechanisms underlying these problems are not well understood and therefore treatment options are limited. Our research has demonstrated increased levels of chemical messengers (gut hormones) released from the gastrointestinal tract after meals in patients who have previously undergone this type of surgery. These chemical messengers play a role in controlling appetite and interest in food, and increased levels after surgery may reduce interest in eating. Understanding the role of gut hormones in the control of appetite may allow us to use certain medications to block gut hormones and hence increase appetite, allowing patients to eat more and regain weight, preventing nutritional problems after surgery. In this study, the investigators aim to determine whether exaggerated gut hormone secretion causes reduced appetite and interest in food after surgery. The information gained from this study may help us to develop treatments for patients with weight loss and nutritional problems after surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesIreland, Sweden

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 6, 2015
Enrollment StartMar 1, 2015
Primary CompletionMar 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 11.3 years ago

Interventions

Octreotidedrug

Single dose 100mcg octreotide acetate (1mL), subcutaneously to the lower abdomen

Placebodrug

Single dose 0.9% saline (1mL), subcutaneously to the lower abdomen